Indigenously developed Bharat Biotech’s COVID-19 vaccine – COVAXIN, has produced neutralising titres (concentration) against all key emerging variants tested, including the B.1.617 and B.1.1.7, first identified in India and the United Kingdom, the vaccine manufacturer informed on Sunday.
A modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to the vaccine variant (D614G).
Bharat Biotech joint managing director Suchitra Ella cited a study published in peer-reviewed medical journal Clinical Infectious Diseases.
Discussion about this post